基于频域OCT的HARBOR研究中新生血管性年龄相关性黄斑变性黄斑萎缩的患病率与进展
本研究对HARBOR试验中1097例新生血管性年龄相关性黄斑变性(nAMD)患者的频域OCT图像进行事后分析,按CAM标准判定黄斑萎缩(MA)。24个月时,不同雷珠单抗剂量与给药方案组间新发MA发生率与进展率均无显著差异。
要点
- 基线时各雷珠单抗组MA患病率存在不均衡:0.5mg每月组19.1%,0.5mg PRN组16.1%,2.0mg每月组10.1%,2.0mg PRN组10.5%。
- 24个月时,无基线MA眼的新发MA率在剂量间(0.5mg 25.9% vs 2.0mg 25.4%)与方案间(每月26.4% vs PRN 25.0%)相似。
- 新发萎缩面积扩大率(P=0.479)与新发MA检出时间(P=0.997)在各研究组间无显著差异。
核心结论
- 在使用CAM萎缩标准的nAMD大型试验分析中,各研究组、雷珠单抗剂量或治疗方案间新发MA的发生率或进展率均无差异。
- 每月与PRN治疗未影响MA的发生率或进展。
研究设计与样本
- HARBOR试验(ClinicalTrials.gov标识NCT00891735)的频域OCT图像事后分析,该试验为3期多中心、前瞻性、随机、双盲、阳性治疗对照临床试验。
- 纳入1097例继发于nAMD的视网膜下中心凹脉络膜新生血管患者,分别接受雷珠单抗0.5mg每月(n=275)、0.5mg负荷3次后PRN(n=275)、2.0mg每月(n=274)或2.0mg PRN(n=273)治疗。
- 对完成24个月随访的患者(N=941)的可评估SD OCT黄斑立方扫描,由设盲的阅读中心培训评分员从基线至第24个月每月进行评估。
主要发现
- 基线时各雷珠单抗组MA患病率存在不均衡:0.5mg每月组19.1%,0.5mg PRN组16.1%,2.0mg每月组10.1%,2.0mg PRN组10.5%。
- 第24个月时,无基线MA眼的新发MA率在雷珠单抗剂量间相似(0.5mg组25.9% vs 2.0mg组25.4%),在治疗方案间也相似(每月组26.4% vs PRN组25.0%)。
- 新发萎缩面积扩大率(平方根转换后P=0.479)与新发MA检出时间(P=0.997)在各研究组间无显著差异。
关键数值与推荐
- 萎缩诊断标准与萎缩分类会议(CAM)组提出的标准一致:光线透见脉络膜、视网膜色素上皮丢失、外层视网膜丢失。
- 满足全部3条标准判定为明确MA,满足2条判定为疑似MA。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Previous studies of macular atrophy (MA) in HARBOR analyzed color fundus photography and fluorescein angiography image data. This study performed a longitudinal assessment of monthly spectral-domain (SD) OCT scans to determine MA prevalence, incidence, and progression in HARBOR. DESIGN: Post hoc analysis of SD OCT images from HARBOR (ClincalTrials.gov identifier, NCT00891735), a phase 3 multicenter, prospective, randomized, double-blind, active treatment-controlled clinical trial. PARTICIPANTS: Patients (n = 1097) with subfoveal choroidal neovascularization secondary to neovascular age-related macular degeneration (nAMD) treated with ranibizumab 0.5 mg monthly (n = 275), 0.5 mg pro re nata (PRN) after 3 loading doses (n = 275), 2.0 mg monthly (n = 274), or 2.0 mg PRN (n = 273). METHODS: Evaluable SD OCT macular cube scans from patients with 24 months of follow-up (N = 941) were examined by masked reading center-trained graders monthly from baseline to month 24. Atrophy diagnosis criteria were consistent with those proposed by the Classification of Atrophy Meetings (CAM) group: hypertransmission of light into the choroid, retinal pigment epithelium loss, and loss of outer retinal layers. Macular atrophy was considered Definite if all 3 criteria were met and Questionable if 2 were met. Study arms were compared for time to MA detection (log-rank test) and enlargement rates (time × arm interaction test). MAIN OUTCOME MEASURES: Prevalence, incidence, and enlargement rates of MA. RESULTS: At baseline, imbalance in MA rates across ranibizumab arms was evident (0.5 mg monthly, 19.1%; 0.5 mg PRN, 16.1%; 2.0 mg monthly, 10.1%; 2.0 mg PRN, 10.5%). At month 24, new MA development rates in eyes without baseline MA were similar between ranibizumab doses (0.5 mg, 25.9%; 2.0 mg, 25.4%) and treatment regimens (monthly, 26.4%; PRN, 25.0%). No significant differences in enlargement rate of new atrophy area (P = 0.479, square-root transformed) or time to detection of new MA (P = 0.997) were evident among study arms. CONCLUSIONS: In this analysis of a major nAMD trial using CAM atrophy criteria, no differences were observed in incidence or progression rates of new MA among study arms, ranibizumab doses, or treatment regimens. Monthly versus PRN treatment did not influence MA incidence or progression.
引用
- Gune S, Abdelfattah NS, Karamat A, et al. Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2019. PMID: 31718842. doi:10.1016/j.ophtha.2019.09.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。